ID
35665
Description
Study ID: 103369 Clinical Study ID: 103369 Study Title: A Randomized Phase III Study of Cisplatin Versus Cisplatin plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: Topotecan Study Indication: Cancer
Keywords
Versions (1)
- 3/14/19 3/14/19 -
Copyright Holder
GSK group of companies
Uploaded on
March 14, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Cisplatin and Topotecan Recurrent or Persistent Carcinoma of the Cervix - 103369
Common Toxicity Report
- StudyEvent: ODM
Description
Common Toxicity Report
Description
The toxicities listed below occurred following this course of therapy
Data type
integer
Description
CTC Term
Data type
text
Description
CTC Grade
Data type
integer
Description
potential connection to Rx
Data type
text
Description
CTEP AER
Data type
boolean
Description
(e.g., lab values, clarifications)
Data type
text
Description
Date
Data type
date
Description
administration at the course of therapy
Data type
text
Description
hospitalisation
Data type
boolean
Description
cytokines administered
Data type
text
Description
Comments
Data type
text
Similar models
Common Toxicity Report
- StudyEvent: ODM